Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » Medicine » Neurologic Disorders » Perspectives on Alzheimer's Disease Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
A Closer Look at Climate Change
$82.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Mild Cognitive Impairment: An Overview (pp. 103-113)
Tell A Friend
 
Tell someone you know about this product.
Mild Cognitive Impairment: An Overview (pp. 103-113) $100.00
Authors:  (M.S. Henry, D. Craig, J.A. Johnston, A.P. Passmore and B. McGuinness)
Abstract:
In an ageing population with a projected large increase in the burden of Alzheimer‘s disease (AD) on patients, carers and health care provision, there has recently been great interest in the concept of identifying those high-risk individuals in the area between normal cognition and dementia for whom early treatment may be beneficial in slowing or even halting progression of cognitive decline.
Mild cognitive impairment (MCI) is a syndrome defined as cognitive decline greater than expected for an individual‘s age and education level, but with preserved activities of daily living. Studies have confirmed an increased rate of progression to dementia in patients diagnosed with MCI (approximately 12% per year), with particular interest in the subtype of amnestic MCI (a-MCI) as a precursor to AD. Indeed some authors have described the clinical phenotype of amnestic MCI as mirroring that of fully expressed AD, only reflecting a milder stage.
Diagnostic testing and elucidation of early disease markers are important evolving concepts in the field of MCI research. Neuroimaging studies with MRI have shown characteristic patterns of atrophy, especially in medial temporal lobes, and white matter changes in MCI patients. Metabolic imaging with positron emission tomography (PET) is a promising modality for detection of functional abnormalities. Cerebrospinal fluid biomarkers such as beta-amyloid and tau may help to identify those patients at risk of decline from MCI to AD. Other studies have associated severity of episodic memory deficits and neuropsychiatric symptoms with progression to dementia.
MCI, however, is a heterogeneous condition which presents problems with respect to diagnosis and study variability. We discuss current thinking regarding the aetiology, diagnostic criteria and sub-typing of this syndrome. 


Available Options:
Version:
This Item Is Currently Unavailable.
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.The New Science of Curiosity
03.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
04.Chronic Disease and Disability: The Pediatric Lung
05.Fruit and Vegetable Consumption and Health: New Research
06.Future Perspectives on Nigella sativa: Characterization and Pharmacological Properties
07.Wine and Winemaking: The Value and Efficiency
08.Impacts and Challenges in Oil Palm Cultivation and Downstream Applications of Biomass
09.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2
10.The Life and Times of the World's Most Famous Mathematicians
11.Innovation Processes in the Social Space of the Organization
12.High-Strength Steels: New Trends in Production and Applications

Nova Science Publishers
© Copyright 2004 - 2018

Mild Cognitive Impairment: An Overview (pp. 103-113)